Evidence map›Paper›PMID 40837344›Full record

ReviewWorld journal of diabetes2025

Role of alternative oral therapy for the management of wet age-related macular degeneration and proliferative diabetic retinopathy.

Shweta Walia, Arvind Kumar Morya, Srishti Khullar, Sarita Aggarwal, Rajwinder Kaur

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shweta WaliaDepartment of Ophthalmology, MGM Medical College, Indore 452001, Madhya Pradesh, India.
Arvind Kumar MoryaDepartment of Ophthalmology, All India Institute of Medical Sciences, Hyderabad 508126, Telangana, India. bulbul.morya@gmail.com.
Srishti KhullarDepartment of Ophthalmology, Military Hospital, Agra 282001, Uttar Pradesh, India.
Sarita AggarwalDepartment of Ophthalmology, Santosh Deemed to be University, Ghaziabad, Ghaziabad 201009, Uttar Pradesh, India.
Rajwinder KaurDepartment of Ophthalmology, Adesh Institute of Medical Sciences and Research, Bathinda 151101, Punjab, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proliferative diabetic retinopathy (PDR) affects approximately 6% of diabetic patients globally. The overall prevalence of diabetic retinopathy is around 22%. Wet age-related macular degeneration (ARMD), the sight-threatening type of ARMD, affects approximately 1.2%-1.3% of the general population and represents 15% of total ARMD cases. While intravitreal anti-vascular endothelial growth factor injections are still the mainstay therapy, there are a few challenges, such as frequent administration, cost burden, and compliance barriers that prompt the need for exploration into systemic oral alternative drugs like fenofibrate, candesartan, and vorolanib. These oral therapies have the advantage of being non-invasive and systemically accessible with few logistical burdens. This review highlights current evidence supporting the use of oral therapies in PDR and wet ARMD management, along with practical limitations and future prospects.

Indexed as

Anti-angiogenesisCandesartanDiabetic macular edemaFenofibrateOral therapyProliferative diabetic retinopathyRetinal neovascularizationSystemic treatmentVorolanibWet age-related macular degeneration

Identifiers

PMID40837344
PMCPMC12362450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.